1.73  0.01 (0.58%)		10-28 14:59
Open: 1.74 High: 1.75 Volume: 83,731		Pre. Close: 1.72 Low: 1.7 Market Cap: 144(M)

Short term
Mid term
Targets	6-month :	2.32	1-year :	2.62
Resists	First :	1.99	Second :	2.25
Pivot price	1.74
Supports	First :	1.58	Second :	1.31
MAs	MA(5) :	1.7	MA(20) :	1.77
	MA(100) :	2.09	MA(250) :	1.43
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	21.8	D(3) :	18.4
RSI	RSI(14): 46.1
52-week	High :	6.19	Low :	0.55

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CTOR ] has closed below upper band by 50.0%. Bollinger Bands are 86.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.76 - 1.77	1.77 - 1.78
Low:	1.66 - 1.67	1.67 - 1.68
Close:	1.7 - 1.72	1.72 - 1.74

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Thu, 23 Oct 2025
Citius Oncology Prepares LYMPHIR Launch for Q4 2025 - TipRanks

Thu, 23 Oct 2025
Citius Oncology, Inc. Updates on LYMPHIR Launch Plans - TradingView

Mon, 20 Oct 2025
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch - PR Newswire

Fri, 17 Oct 2025
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - PR Newswire

Tue, 07 Oct 2025
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire

Sat, 27 Sep 2025
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Turn A Profit? - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	84 (M)
Shares Float	11 (M)
Held by Insiders	88.6 (%)
Held by Institutions	0.7 (%)
Shares Short	151 (K)
Shares Short P.Month	136 (K)

EPS	-0.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.44
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-22.5 %
Return on Equity (ttm)	-107.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-4.47
PEG Ratio	0
Price to Book value	3.86
Price to Sales	0
Price to Cash Flow	1150.1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.